The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Open accessAbstract
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials, resulting in regulatory approvals for the treatment of selected patients with breast cancer, certain other solid tumours or particular haematological malignancies. However, given the prominence of PI3K signalling in cancer and the crucial role of this pathway in linking cancer growth with metabolism, these clinical results could arguably be improved upon. In this Review, we discuss past and present efforts to overcome the somewhat limited clinical efficacy of PI3Kα pathway inhibitors, including optimization of inhibitor specificity, patient selection and biomarkers across cancer types, with a focus on breast cancer, as well as identification and abrogation of signalling-related and metabolic mechanisms of resistance, and interventions to improve management of prohibitive adverse events. We highlight the advantages and limitations of laboratory-based model systems used to study the PI3K pathway, and propose technologies and experimental inquiries to guide the future clinical deployment of PI3K pathway inhibitors in the treatment of cancer. Several PI3K pathway inhibitors are currently approved as cancer treatments; however, finding an acceptable therapeutic window to target this key signalling cascade linking cancer growth with metabolism has proven challenging and the clinical results to date have arguably been disappointing. In this Review, Vasan and Cantley discuss the effects of PI3K pathway alterations on signalling and metabolism in solid tumours as well as past and present efforts to improve the somewhat limited clinical efficacy of PI3K pathway inhibitors, with a particular focus on PI3Kα in breast cancers. PIK3CA is one of the most frequently mutated genes in cancer; the PI3K pathway is altered in a large number of cancer types, driving cell signalling, growth and metabolism, and PI3K inhibitors have been in development for over four decades. Seven drugs that target the PI3K pathway have received regular or accelerated approval from the FDA, including alpelisib in combination with fulvestrant for advanced-stage, PIK3CA-mutant, oestrogen receptor-positive breast cancer. AKT inhibitors and next-generation mTOR inhibitors are currently being tested in early phase and late-phase clinical trials. Adaptive signalling, epigenetic and metabolic changes in cancer cells can limit the clinical efficacy of PI3K inhibitors. In addition, PI3K inhibition in non-cancer cells causes hyperglycaemia and other on-target adverse effects that limit patient tolerability, as well as hyperinsulinaemia, which can lead to reactivation of cancer cells; the net effect of these alterations is attenuation of PI3K inhibitor efficacy. Targeting insulin signalling, improved management of hyperglycaemia, development of mutant-specific PI3K inhibitors, and validation of refined biomarkers of response and resistance are novel translational strategies currently being tested to improve the therapeutic window of PI3K inhibitors in patients with cancer. Genomic, transcriptomic, proteomic, phosphoproteomic and metabolomic analyses of patients with PIK3CA-mutant tumours receiving PI3K inhibitors are needed to discover new pathways for combination therapies in different cancer types. PIK3CA is one of the most frequently mutated genes in cancer; the PI3K pathway is altered in a large number of cancer types, driving cell signalling, growth and metabolism, and PI3K inhibitors have been in development for over four decades. Seven drugs that target the PI3K pathway have received regular or accelerated approval from the FDA, including alpelisib in combination with fulvestrant for advanced-stage, PIK3CA-mutant, oestrogen receptor-positive breast cancer. AKT inhibitors and next-generation mTOR inhibitors are currently being tested in early phase and late-phase clinical trials. Adaptive signalling, epigenetic and metabolic changes in cancer cells can limit the clinical efficacy of PI3K inhibitors. In addition, PI3K inhibition in non-cancer cells causes hyperglycaemia and other on-target adverse effects that limit patient tolerability, as well as hyperinsulinaemia, which can lead to reactivation of cancer cells; the net effect of these alterations is attenuation of PI3K inhibitor efficacy. Targeting insulin signalling, improved management of hyperglycaemia, development of mutant-specific PI3K inhibitors, and validation of refined biomarkers of response and resistance are novel translational strategies currently being tested to improve the therapeutic window of PI3K inhibitors in patients with cancer. Genomic, transcriptomic, proteomic, phosphoproteomic and metabolomic analyses of patients with PIK3CA-mutant tumours receiving PI3K inhibitors are needed to discover new pathways for combination therapies in different cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationAKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 3×
“Mutations in p85α occur rarely in cancer and result in PI3K pathway activation through complex mechanisms, including (1) a p110α- dependent hypermorphic mechanism whereby hemizygous loss of p85α increases p110α–p85α binding to activated RTKs, thus causing oncogenic transformation in mouse models (indicating a tumour-…”
BackgroundSelf-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Self-citation
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2994 · Cited by 91
(2023) · doi:10.1158/2159-8290.cd-23-0396 · Cited by 80
Metadata
- Authors
- Vasan, N., & Cantley, L. C.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2022-04-28
- Volume
- 19
- Issue
- 7
- Pages
- 471-485
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4225122437
- Cited by
- 163
- References
- 32
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. https://app.cochat.ai/papers/10.1038/s41571-022-00633-1
- The paper
- Vasan, N., & Cantley, L. C. (2022). At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-022-00633-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.